Analysts Issue Forecasts for Brainsway Q1 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities researchers at Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for Brainsway in a research note issued to investors on Thursday, January 22nd. Northland Securities analyst C. Byrnes forecasts that the company will earn $0.08 per share for the quarter. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q2 2026 earnings at $0.12 EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.64 EPS.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.03). Brainsway had a return on equity of 9.46% and a net margin of 12.73%.The firm had revenue of $13.51 million for the quarter, compared to the consensus estimate of $13.04 million.

BWAY has been the subject of several other reports. Wall Street Zen lowered Brainsway from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright raised their target price on Brainsway from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Brainsway has an average rating of “Moderate Buy” and an average price target of $27.00.

Brainsway Stock Down 4.8%

Shares of NASDAQ BWAY opened at $23.04 on Friday. The company has a market capitalization of $451.12 million, a PE ratio of 76.80 and a beta of 1.19. Brainsway has a twelve month low of $7.84 and a twelve month high of $24.84. The firm has a fifty day simple moving average of $18.88 and a 200 day simple moving average of $16.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BWAY. Palumbo Wealth Management LLC increased its holdings in shares of Brainsway by 37.9% during the fourth quarter. Palumbo Wealth Management LLC now owns 16,320 shares of the company’s stock valued at $310,000 after acquiring an additional 4,483 shares in the last quarter. Y.D. More Investments Ltd lifted its holdings in shares of Brainsway by 559.8% in the 4th quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after purchasing an additional 97,537 shares in the last quarter. NewEdge Advisors LLC grew its position in Brainsway by 7.4% in the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock valued at $431,000 after purchasing an additional 1,964 shares during the period. Millennium Management LLC increased its stake in Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after purchasing an additional 16,354 shares in the last quarter. Finally, Centiva Capital LP acquired a new position in Brainsway during the third quarter worth $181,000. Institutional investors own 30.11% of the company’s stock.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.